logo
Our Galaxy's Monster Black Hole Is Spinning Almost as Fast as Physics Allows

Our Galaxy's Monster Black Hole Is Spinning Almost as Fast as Physics Allows

Yahoo19-06-2025
The colossal black hole lurking at the center of the Milky Way galaxy is spinning almost as fast as its maximum rotation rate.
That's just one thing astrophysicists have discovered after developing and applying a new method to tease apart the secrets still hidden in supermassive black hole observations collected by the Event Horizon Telescope (EHT).
The unprecedented global collaboration spent years working to give us the first direct images of the shadows of black holes, first with M87* in a galaxy 55 million light-years away, then with Sgr A*, the supermassive black hole at the heart of our own galaxy.
These images are incredible – but also difficult to interpret. So, to figure out what we're looking at, scientists turn to simulations. They build a bunch of virtual characteristics, and figure out which of them most resemble the observational data. This technique has been used a lot with the EHT images, but now it's been kicked up a notch.
A team led by astronomer Michael Janssen of Radboud University in the Netherlands and the Max Planck Institute for Radio Astronomy in Germany used high-throughput computing to develop millions of simulated black holes.
Then, they used that data to train a neural network to extract as much information as possible from the data, and identify the properties of the black holes.
Their results show, among other things, that Sgr A* is not only spinning at close to its maximum speed, but that its rotational axis is pointed in Earth's direction, and that the glow around it is generated by hot electrons.
Perhaps the most interesting thing is that the magnetic field in the material around Sgr A* doesn't appear to be behaving in a way that's predicted by theory.
M87*, they discovered, is also rotating rapidly, although not as fast as Sgr A*. However, it is rotating in the opposite direction to the material swirling in a disk around it – possibly because of a past merger with another supermassive black hole.
"That we are defying the prevailing theory is of course exciting," Janssen says.
"However, I see our AI and machine learning approach primarily as a first step. Next, we will improve and extend the associated models and simulations. And when the Africa Millimetre Telescope, which is under construction, joins in with data collection, we will get even better information to validate the general theory of relativity for supermassive compact objects with a high precision."
The team has detailed their methodology and findings in three papers published in Astronomy & Astrophysics. They can be found here, here, and here.
Did a Passing Star Cause Earth to Warm 56 Million Years Ago?
A Game-Changing Telescope Is About to Drop First Pics. Here's How to Watch.
Trailblazing Satellite Mission Delivers Its First Artificial Solar Eclipse
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Microaxial Flow Pump Reduces Heart Load in Post-MI Shock
Microaxial Flow Pump Reduces Heart Load in Post-MI Shock

Medscape

timean hour ago

  • Medscape

Microaxial Flow Pump Reduces Heart Load in Post-MI Shock

TOPLINE: In patients with ST-segment elevation myocardial infarction (STEMI)-induced cardiogenic shock undergoing hemodynamic monitoring with a pulmonary artery catheter, the use of a microaxial flow pump (mAFP; Impella) reduced the intrinsic mechanical work performed by the heart by reducing native cardiac output and pulmonary pressures while maintaining the power output delivered to the body. METHODOLOGY: A previous Danish-German trial showed reduced mortality with early placement of an mAFP in patients with cardiogenic shock following STEMI. In this substudy, researchers analyzed data of 223 patients monitored in the cardiac ICU with a pulmonary artery catheter to determine the effects of the device on hemodynamics in STEMI-induced cardiogenic shock. Patients had been randomly assigned to receive either standard care (n = 98; median age, 67 years; 78% men) or an mAFP plus standard care (n = 125; median age, 65 years; 82% men). Outcomes included cardiac output, mean pulmonary artery pressure, and cardiac power output during the first 48 hours after admission to the cardiac ICU; native cardiac output was defined as the patient's total cardiac output minus the estimated mAFP flow. TAKEAWAY: After the initial 6 hours in the cardiac ICU, cardiac output continued to improve in the mAFP group and remained consistently higher than in the standard care group from 12 to 48 hours (P < .001). Native cardiac output also improved after 6 hours but stayed significantly lower in the mAFP group than in the standard care group. Mean pulmonary artery pressure was initially lower in the mAFP group than in the standard care group (median, 27 vs 31 mm Hg; P < .001) and remained lower at 48 hours. Pulmonary capillary wedge pressure was also lower in the patients with an mAFP. The initial cardiac power output within 3 hours of arrival to the cardiac ICU was 0.56 W in the standard care group vs 0.68 W in the mAFP group (P = .01), which improved over the next 48 hours. The mAFP group required lesser vasoactive and inotropic support than the standard care group for the first 6 hours and had lower mortality at 180 days. IN PRACTICE: 'We consistently found lower pulmonary pressures and a PCWP [pulmonary capillary wedge pressure] during mAFP support, each of which provides confirmation of LV [left ventricular] unloading while on mAFP. Reducing these pressures helps alleviate pulmonary edema, reduce right ventricular afterload, and enhance forward flow,' the researchers wrote. 'By reducing myocardial work and wall stress, unloading may be protective in stunned, postischemic myocardium vulnerable to further insult,' the authors of an editorial accompanying the journal article wrote. SOURCE: This study was led by Jacob Eifer Møller, MD, DMSc, Odense University Hospital, Odense, Denmark. It was published online on June 23, 2025, in Journal of the American College of Cardiology. LIMITATIONS: Pulmonary artery catheter was used more frequently in patients randomized to the mAFP group compared with the standard care group. Data capture may not have been streamlined or complete as this study involved patients who were critically ill, unstable, and had imminent need for treatment. Hemodynamic monitoring was limited to the first 48 hours and did not account for long-term effects or changes. DISCLOSURES: The original trial was supported by the Danish Heart Foundation and Abiomed. Several authors reported receiving research, educational, and/or travel grants, speaker fees, and honoraria; serving on advisory boards; holding stock options; and having other financial ties with various pharmaceutical, healthcare, and other companies, including Abiomed, Novo Nordisk Foundation, and Boston Scientific. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

NASA Wants to Bring Livestreams to Netflix
NASA Wants to Bring Livestreams to Netflix

Yahoo

time2 hours ago

  • Yahoo

NASA Wants to Bring Livestreams to Netflix

Starting in summer 2025, Netflix will expand its offerings with an unusual collaboration: The U.S. space agency NASA will bring its livestream program NASA+ to the streaming platform. With a new partnership, NASA is taking another step to make its content accessible to a global audience: Starting in summer 2025, NASA+'s live programming will also be available on Netflix. The partnership with Netflix expands this offering with additional reach–especially on devices where the NASA app was previously unavailable. The NASA+ livestreams will soon appear on the regular Netflix interface, right alongside series and movies. Users will be able to stream real-time broadcasts of missions, spacewalks, and spectacular views of Earth from 400 kilometers above. Rocket launches will also be regularly available live. There is no additional cost for users; the offering is included in all Netflix subscriptions and is ad-free. NASA aims to strengthen interest in science and space exploration through this partnership. 'Our mission is to tell the story of space exploration to the widest possible audience,' explains Rebecca Sirmons, General Manager of NASA+. The partnership with Netflix is a step into a 'golden era of innovation and discovery,' Sirmons adds. For years, the agency has relied on audiovisual content to showcase its work. The new presence on Netflix is intended to elevate this approach to a new level. For Netflix, the collaboration with NASA also means an expansion of its live offerings. The streaming service has increasingly invested in live formats such as sports broadcasts and show events in recent months. The NASA+ livestreams fit into this strategy and simultaneously open up a new thematic field. Also read: Netflix Reveals All New Releases for July Another advantage of the Netflix integration is broader device availability. While the NASA app is available on platforms like iOS, Android, Roku, and Apple TV, it has been missing on gaming consoles and certain smart TVs. By integrating with Netflix, users of such devices can access NASA content without additional app installation or registration. Specific launch dates and program details for NASA+ livestreams on Netflix will be announced in the coming weeks. Netflix mentions only that NASA+ content will be available by the end of the summer. Until then, access to NASA+ remains available through the agency's website and official apps. However, the partnership with Netflix already marks a significant step in making space exploration more visible to a global audience. The post NASA Wants to Bring Livestreams to Netflix appeared first on TECHBOOK.

Apheresis May Sweep Microplastics From Veins
Apheresis May Sweep Microplastics From Veins

Medscape

time5 hours ago

  • Medscape

Apheresis May Sweep Microplastics From Veins

Microplastics are particles ranging from 1 micrometer to 5 millimeters in diameter, and nanoplastics, which are even smaller, are found in virtually every environment on Earth, from mountain peaks to ocean depths, and from the smallest animals in the food chain to human brain cells. These particles can originate from the breakdown of larger plastic items or be intentionally manufactured for use in products, such as cosmetics, synthetic fabrics, and pharmaceuticals. Recent studies suggest that the human brain may contain up to a teaspoon of microplastics and nanoplastics, with the tiniest fragments primarily composed of polyethylene, the same material commonly used in plastic bags and food packaging. These particles have been detected in areas such as the walls of blood vessels in the brain and within immune cells. However, it remains unclear whether microplastics contribute to the progression of neurological diseases or whether these conditions render the brain more susceptible to particle infiltration. In animal studies involving fish and rodents, prolonged exposure to nanoplastics has been linked to memory impairment, brain inflammation, and alterations in synaptic protein levels. Beyond the brain, microplastics have been found in human feces, arterial plaques, and even the placenta. A study published in The New England Journal of Medicine linked the presence of microplastics in the arteries to a heightened risk for heart attack, stroke, and overall mortality. Therapeutic Apheresis According to a preliminary study published in Brain Medicine by researchers at Technische Universität Dresden in Dresden, Germany, therapeutic apheresis, a medical procedure that filters tiny particles from the blood, may help remove microplastics from the human body. The technique can capture particles as small as 200 nanometers, which is approximately 5000 times smaller than a millimeter. In this study, the researchers evaluated the procedure in patients with myalgic encephalomyelitis, also known as chronic fatigue syndrome. They analyzed the waste fluid discarded during apheresis using a specialized infrared spectroscopy technique. The analysis detected substances that matched the chemical signatures of polyamide and polyurethane, two common types of industrial plastics. This suggests that microplastics may have been successfully removed from the blood of patients during the procedure. Notably, this study did not measure the total amount of microplastics removed or compare their levels in patients before and after apheresis. What has been demonstrated so far is the presence of microplastics in the waste material discarded by the device — an observation that suggests, but does not yet confirm, the effective removal of these substances from the human body. Researchers have cautioned that the detected materials may reflect chemical structures common to proteins, meaning that further analysis is required to verify the exact nature of the removed particles. Nonetheless, the findings offer hope to researchers seeking to address the growing accumulation of microplastics in the human body. The authors recommended conducting studies with larger groups and quantitative analyses comparing the levels of microplastics in the blood before and after the procedures. The authors concluded that 'such analyses will help determine particle removal from blood and tissues and assess correlations with symptom improvement in conditions like myalgia encephalomyelitis/chronic fatigue syndrome.' Alternative Approaches Currently, evidence that microplastics are effectively removed from the human body after ingestion is limited. A 2011 study examined bisphenol A (BPA) levels in blood, sweat, and urine samples from 20 individuals. In 16 cases, BPA appeared only in sweat, suggesting that induced perspiration may help eliminate certain compounds from the body. However, more studies are needed to assess its long-term safety and efficacy. 'That is why we focus on reducing exposure to microplastics in the first place,' said Nicholas Fabiano, MD, a psychiatry resident at the University of Ottawa, Ottawa, Ontario, Canada, and co-author of a related article in Brain Medicine . The challenge of this research began with tracking the effects of microplastic particles. 'From a clinical perspective, it is very difficult to establish a direct link between exposure to microplastics and adverse health outcomes,' said Fabiano. To address this, he advocated the creation of new tools to measure dietary risks, such as a dietary microplastic index. 'We propose the development of a Dietary Microplastic Index that could be integrated with existing dietary risk assessment tools to estimate microplastic exposure based on the types of food consumed,' he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store